---
{"dg-publish":true,"permalink":"/5//asco-2024-ct-dna-psm-afore-177-lu-psma-617-m-crpc/"}
---


# ASCO 2024: åŸºçº¿ctDNAåˆ†æåŠå…¶ä¸åœ¨PSMAforeä¸­ä½¿ç”¨177Lu-PSMA-617æ²»ç–—çš„æœªæ¥å—è¿‡ç´«æ‰çƒ·æ²»ç–—çš„mCRPCæ‚£è€…çš„ç»“æœå…³è”æ€§

### æ¦‚è¿°
2024å¹´ç¾å›½ä¸´åºŠè‚¿ç˜¤å­¦ä¼šï¼ˆASCOï¼‰å¹´ä¼šä¸Šï¼Œçº¦ç¿°Â·å¾·Â·åšè¯ºåšå£«å±•ç¤ºäº†åŸºçº¿å¾ªç¯è‚¿ç˜¤DNAï¼ˆctDNAï¼‰åˆ†æåŠå…¶ä¸æœªæ¥å—è¿‡ç´«æ‰çƒ·æ²»ç–—çš„è½¬ç§»æ€§å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œï¼ˆmCRPCï¼‰æ‚£è€…ä½¿ç”¨177Lu-PSMA-617æ²»ç–—ç›¸æ¯”äºæ›´æ¢é›„æ¿€ç´ å—ä½“é€šè·¯æŠ‘åˆ¶å‰‚ï¼ˆARPIï¼‰çš„ç»“æœå…³è”æ€§ã€‚

### äº®ç‚¹
- ğŸ§¬ **åŸºçº¿ctDNAä¸é¢„åå…³è”**ï¼šè¾ƒé«˜çš„åŸºçº¿ctDNAæ¯”ä¾‹ä¸è¾ƒçŸ­çš„å½±åƒå­¦æ— è¿›å±•ç”Ÿå­˜æœŸç›¸å…³ã€‚
- ğŸ’Š **177Lu-PSMA-617ç–—æ•ˆæ˜¾è‘—**ï¼šä¸è®ºåŸºçº¿ctDNAæ¯”ä¾‹å¦‚ä½•ï¼Œä½¿ç”¨177Lu-PSMA-617çš„æ‚£è€…æ¯”æ›´æ¢ARPIçš„æ‚£è€…æœ‰æ›´é•¿çš„æ— è¿›å±•ç”Ÿå­˜æœŸã€‚
- ğŸ“‰ **æ—©æœŸctDNAæ¸…é™¤æ•ˆæœ**ï¼šæ—©æœŸctDNAæ¸…é™¤ä¸æ›´é•¿çš„å½±åƒå­¦æ— è¿›å±•ç”Ÿå­˜æœŸç›¸å…³ã€‚
- ğŸ”¬ **é‡è¦åŸºå› å˜å¼‚**ï¼š8qæ‰©å¢ã€ARæ‰©å¢å’ŒTP53æœ‰å®³å˜å¼‚æ˜¯é¢„åç”Ÿç‰©æ ‡å¿—ç‰©ï¼Œå‡ä¸è¾ƒçŸ­çš„å½±åƒå­¦æ— è¿›å±•ç”Ÿå­˜æœŸåŠé™ä½çš„è‚¿ç˜¤ååº”æœ‰å…³ã€‚

### é…å›¾

1.  ![è¯•éªŒè®¾è®¡](https://proxy-prod.omnivore-image-cache.app/624x232,sCYDS59nve9ULIrA725v1-ERsnNZNiNHC_yO4q--N1CY/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-baseline-ctdna-analyses-and-associations-with-outcomes-in-taxane-naive-patients-with-mcrpc-treated-with-177lu-psma-617-versus-change-of-arpi-in-psmafore/image-0.jpg)
{ #32c7f4}

   - æœ¬å›¾å±•ç¤ºäº†è¯•éªŒè®¾è®¡ï¼ŒåŒ…æ‹¬éšæœºåˆ†é…å’Œä¸»è¦ç»ˆç‚¹ã€‚

2. ![177Lu-PSMA-617 ctDNA analysis](https://proxy-prod.omnivore-image-cache.app/624x255,se89tbwtWi2MKGIc5lfbOvT5vYZLngkkwxRXj7Zv93CE/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-baseline-ctdna-analyses-and-associations-with-outcomes-in-taxane-naive-patients-with-mcrpc-treated-with-177lu-psma-617-versus-change-of-arpi-in-psmafore/image-1.jpg)
  
   è§£é‡Šï¼šè¿™å¼ å›¾ç‰‡å¯èƒ½å±•ç¤ºäº†å¾ªç¯è‚¿ç˜¤DNAï¼ˆctDNAï¼‰åˆ†æçš„è®¾è®¡å›¾ï¼ŒåŒ…æ‹¬æŠ½å–è¡€æ¶²æ ·æœ¬ã€æå–ctDNAã€è¿›è¡ŒåŸºå› æµ‹åºå’Œåˆ†æç­‰æ­¥éª¤ã€‚
{ #d0020e}


3. ![177Lu-PSMA-617 flow](https://proxy-prod.omnivore-image-cache.app/624x254,sE8bxqZBoNqhUMDTq-1M7Wn3ndrBskBo7M0R-3tMbcrk/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-baseline-ctdna-analyses-and-associations-with-outcomes-in-taxane-naive-patients-with-mcrpc-treated-with-177lu-psma-617-versus-change-of-arpi-in-psmafore/image-2.jpg)
  
   è§£é‡Šï¼šè¿™å¼ å›¾ç‰‡å¯èƒ½è¯´æ˜äº†ç ”ç©¶ä¸­æ ·æœ¬ç­›é€‰æµç¨‹ï¼Œå¦‚ä½•ä»æ‚£è€…æ ·æœ¬ä¸­ç­›é€‰å‡ºé€‚åˆåˆ†æçš„ctDNAã€‚
{ #21bfe2}


4. ![177Lu-PSMA-617 ctdna analysis proportion of patients without rPFS](https://proxy-prod.omnivore-image-cache.app/624x240,sCMOpZ6Hn8oTfE1k0frU1CR4zZbwBNXDgAHdTFR89kbo/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-baseline-ctdna-analyses-and-associations-with-outcomes-in-taxane-naive-patients-with-mcrpc-treated-with-177lu-psma-617-versus-change-of-arpi-in-psmafore/image-3.jpg)
  
   è§£é‡Šï¼šè¿™å¼ å›¾ç‰‡æœ‰å¯èƒ½å±•ç¤ºäº†åŸºçº¿ctDNAæ¯”ä¾‹ä¸æ— å½±åƒå­¦è¿›å±•ç”Ÿå­˜æœŸï¼ˆrPFSï¼‰ä¹‹é—´çš„å…³ç³»ï¼Œå³ä¸åŒçš„ctDNAæ°´å¹³å¦‚ä½•å½±å“æ‚£è€…é¢„åã€‚

5. ![177Lu-PSMA-617 prolonged radiographic progression free survival compared with androgen receptor pathway inhibitor change regardless of baseline ctDNA fraction](https://proxy-prod.omnivore-image-cache.app/624x252,sKSeDKC40F0NOgrVs4bJQKxCPImu_lhscZH5HlwNHEEk/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-baseline-ctdna-analyses-and-associations-with-outcomes-in-taxane-naive-patients-with-mcrpc-treated-with-177lu-psma-617-versus-change-of-arpi-in-psmafore/image-4.jpg)
   
   è§£é‡Šï¼šè¯¥å›¾å¯èƒ½å¯¹æ¯”äº†ä½¿ç”¨177Lu-PSMA_617ä¸æ›´æ¢é›„æ¿€ç´ å—ä½“é€šè·¯æŠ‘åˆ¶å‰‚æ²»ç–—çš„æ‚£è€…åœ¨æ— å½±åƒå­¦è¿›å±•ç”Ÿå­˜æœŸæ–¹é¢çš„å·®å¼‚ã€‚

6. ![177Lu-PSMA_617 genomic analysis](https://proxy-prod.omnivore-image-cache.app/624x225,sm0Nc9H_pVDtZMXHd0aPjroXlyhk5kSJNe30MdvK9N0M/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-baseline-ctdna-analyses-and-associations-with-outcomes-in-taxane-naive-patients-with-mcrpc-treated-with-177lu-psma-617-versus-change-of-arpi-in-psmafore/image-5.jpg)
   è§£é‡Šï¼šæ˜¾ç¤ºäº†é«˜äº0.5%çš„ctDNAæ¯”ä¾‹å¯¹RECISTååº”å’ŒPSA50ååº”çš„ä¸è‰¯å½±å“ã€‚

7. ![æ—©æœŸæ¸…é™¤æ•ˆæœ](https://proxy-prod.omnivore-image-cache.app/624x255,sVYJO6w0h0TQuZ0Lzjmteuvf54S3LiDaaprWwe3ekOBA/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-baseline-ctdna-analyses-and-associations-with-outcomes-in-taxane-naive-patients-with-mcrpc-treated-with-177lu-psma-617-versus-change-of-arpi-in-psmafore/image-6.jpg)
   - æè¿°äº†æ—©æœŸæ¸…é™¤å¯¹å½±åƒå­¦æ— è¿›å±•ç”Ÿå­˜æœŸçš„æ­£é¢å½±å“ã€‚

8. ![åŸºå› ç‰¹å¾å½±å“](https://proxy-prod.omnivore-image-cache.app/624x250,s7CVScaRAvlcWDuC6Cp9SV-KubmdS8muHu3QfiOJBRUM/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-baseline-ctdna-analyses-and-associations-with-outcomes-in-taxane-naive-patients-with-mcrpc-treated-with-177lu-psma-617-versus-change-of-arpi-in-psmafore/image-7.jpg)
   - å±•ç¤ºäº†æŸäº›å¸¸è§åŸºå› å˜å¼‚ï¼ˆå¦‚8qæ‰©å¢ï¼‰å¯¹å½±åƒå­¦æ— è¿›å±•ç”Ÿå­˜æœŸçš„ä¸åˆ©å½±å“ã€‚

9. ![ARæ‰©å¢å½±å“](https://proxy-prod.omnivore-image-cache.app/624x249,sKpqKiDBwCjZ4W43h0Y8UFkUiJ4gsr29tJs7NtVVJfJQ/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-baseline-ctdna-analyses-and-associations-with-outcomes-in-taxane-naive-patients-with-mcrpc-treated-with-177lu-psma-617-versus-change-of-arpi-in-psmafore/image-8.jpg)
   - æè¿°äº†ARæ‰©å¢å¯¹å½±åƒå­¦æ— è¿›å±•ç”Ÿå­˜æœŸçš„ä¸åˆ©å½±å“ã€‚

10. ![TP53å˜å¼‚å½±å“](https://proxy-prod.omnivore-image-cache.app/624x251,sSlLv_s9USgG2KBp0DlnLr0SVPkNAVyX0Ocr55ZSqHEs/https://www.urotoday.com/images/com-doc-importer/164-asco-2024/asco-2024-baseline-ctdna-analyses-and-associations-with-outcomes-in-taxane-naive-patients-with-mcrpc-treated-with-177lu-psma-617-versus-change-of-arpi-in-psmafore/image-9.jpg)
    - å±•ç¤ºäº†TP53æœ‰å®³å˜å¼‚å¯¹å½±åƒå­¦æ— è¿›å±•ç”Ÿå­˜æœŸçš„ä¸åˆ©å½±å“ã€‚

### ç›¸å…³é—®é¢˜

#### åŸºçº¿ctDNAåˆ†æå¦‚ä½•å½±å“æ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸï¼Ÿ

åŸºçº¿ctDNAåˆ†æå¯ä»¥æä¾›å…³äºæ‚£è€…è‚¿ç˜¤ç‰¹å¾å’Œç–¾ç—…è¿›å±•çš„é‡è¦ä¿¡æ¯ã€‚é€šè¿‡åˆ†æåŸºçº¿ctDNAï¼Œå¯ä»¥ç¡®å®šæ‚£è€…ä½“å†…çš„è‚¿ç˜¤è´Ÿè·å’Œè‚¿ç˜¤çªå˜æƒ…å†µï¼Œä»è€Œé¢„æµ‹æ‚£è€…å¯¹æ²»ç–—çš„ååº”å’Œç–¾ç—…è¿›å±•çš„é£é™©ã€‚åœ¨æ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸæ–¹é¢ï¼Œé«˜åŸºçº¿ctDNAåˆ†æ•°é€šå¸¸ä¸è¾ƒçŸ­çš„è¿›å±•æ— ç—…ç”Ÿå­˜æœŸç›¸å…³è”ï¼Œè¡¨æ˜æ‚£è€…ä½“å†…çš„è‚¿ç˜¤è´Ÿè·è¾ƒé«˜ï¼Œç–¾ç—…å¯èƒ½æ›´å®¹æ˜“è¿›å±•ã€‚å› æ­¤ï¼ŒåŸºçº¿ctDNAåˆ†æå¯ä»¥å¸®åŠ©åŒ»ç”Ÿæ›´å¥½åœ°è¯„ä¼°æ‚£è€…çš„ç–¾ç—…çŠ¶æ€å’Œé¢„æµ‹æ²»ç–—æ•ˆæœï¼Œä»è€ŒæŒ‡å¯¼ä¸ªä½“åŒ–çš„æ²»ç–—ç­–ç•¥ã€‚

#### 177Lu-PSMA-617å’Œé›„æ¿€ç´ å—ä½“é€”å¾„æŠ‘åˆ¶å‰‚å˜åŒ–åœ¨æ²»ç–—è½¬ç§»æ€§å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œæ‚£è€…æ—¶ï¼ŒåŸºçº¿ctDNAåˆ†æä¸ç»“æœçš„å…³è”æ˜¯ä»€ä¹ˆï¼Ÿ

åœ¨æ²»ç–—è½¬ç§»æ€§å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œæ‚£è€…æ—¶ï¼Œé€šè¿‡å¯¹åŸºçº¿ctDNAè¿›è¡Œåˆ†æå¯ä»¥å‘ç°ä¸æ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸã€PSAååº”å’ŒRECISTååº”ç­‰ç»“æœä¹‹é—´çš„å…³è”ã€‚å…·ä½“æ¥è¯´ï¼Œé«˜åŸºçº¿ctDNAåˆ†æ•°ä¸è¾ƒçŸ­çš„æ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸç›¸å…³è”ï¼Œè€Œ177Lu-PSMA-617æ²»ç–—ç›¸å¯¹äºé›„æ¿€ç´ å—ä½“é€”å¾„æŠ‘åˆ¶å‰‚å˜åŒ–åœ¨ä¸åŒåŸºçº¿ctDNAåˆ†æ•°ä¸‹éƒ½èƒ½å»¶é•¿è¿›å±•æ— ç—…ç”Ÿå­˜æœŸã€‚æ­¤å¤–ï¼Œæ—©æœŸctDNAåˆ†æ•°åŠ¨æ€å¯ä»¥æä¾›å…³äºæ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸå’Œè‚¿ç˜¤ååº”çš„ä¿¡æ¯ã€‚å¦å¤–ï¼Œä¸€äº›åŸºå› å˜å¼‚å¦‚8qæ‰©å¢ã€ARæ‰©å¢å’ŒTP53æœ‰å®³å˜å¼‚ä¹Ÿä¸è¾ƒçŸ­çš„æ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸç›¸å…³è”ã€‚

#### åœ¨PSMAforeè¯•éªŒä¸­ï¼Œ177Lu-PSMA-617æ˜¯å¦æ¯”é›„æ¿€ç´ å—ä½“é€”å¾„æŠ‘åˆ¶å‰‚å˜åŒ–æ›´æœ‰æ•ˆï¼Ÿ

åœ¨PSMAforeè¯•éªŒä¸­ï¼Œç ”ç©¶ç»“æœæ˜¾ç¤ºï¼Œ177Lu-PSMA-617ç›¸å¯¹äºé›„æ¿€ç´ å—ä½“é€”å¾„æŠ‘åˆ¶å‰‚å˜åŒ–åœ¨æ²»ç–—è½¬ç§»æ€§å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œæ‚£è€…æ—¶è¡¨ç°å‡ºæ›´æœ‰æ•ˆçš„æ•ˆæœã€‚å…·ä½“æ¥è¯´ï¼Œ177Lu-PSMA-617æ²»ç–—ç»„åœ¨æ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸæ–¹é¢è¡¨ç°æ›´å¥½ï¼Œç›¸è¾ƒäºé›„æ¿€ç´ å—ä½“é€”å¾„æŠ‘åˆ¶å‰‚å˜åŒ–ç»„ï¼Œæ‚£è€…çš„ç–¾ç—…è¿›å±•é£é™©æ›´ä½ã€‚å› æ­¤ï¼Œæ ¹æ®PSMAforeè¯•éªŒçš„ç»“æœï¼Œ177Lu-PSMA-617å¯èƒ½æ˜¯ä¸€ç§æ›´æœ‰æ•ˆçš„æ²»ç–—é€‰æ‹©ï¼Œç‰¹åˆ«æ˜¯å¯¹äºè½¬ç§»æ€§å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œæ‚£è€…ã€‚

#### å“ªäº›åŸºå› å˜å¼‚ä¸è¾ƒçŸ­çš„æ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸç›¸å…³è”ï¼Ÿ

åœ¨ç ”ç©¶ä¸­å‘ç°ï¼Œä¸€äº›åŸºå› å˜å¼‚ä¸è¾ƒçŸ­çš„æ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸç›¸å…³è”ã€‚å…·ä½“æ¥è¯´ï¼Œä»¥ä¸‹åŸºå› å˜å¼‚ä¸è¾ƒçŸ­çš„æ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸæœ‰å…³ï¼š

1. 8qæ‰©å¢ï¼š8qæ‰©å¢çš„å­˜åœ¨ä¸è¾ƒçŸ­çš„æ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸç›¸å…³è”ã€‚
2. ARæ‰©å¢ï¼šé›„æ¿€ç´ å—ä½“ï¼ˆARï¼‰çš„æ‰©å¢ä¹Ÿä¸è¾ƒçŸ­çš„æ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸç›¸å…³ã€‚
3. TP53æœ‰å®³å˜å¼‚ï¼šTP53åŸºå› çš„æœ‰å®³å˜å¼‚ä¸è¾ƒçŸ­çš„æ”¾å°„å½±åƒè¿›å±•æ— ç—…ç”Ÿå­˜æœŸç›¸å…³è”ã€‚

è¿™äº›åŸºå› å˜å¼‚å¯èƒ½å½±å“è‚¿ç˜¤çš„ç”Ÿé•¿ã€è¿›å±•å’Œæ²»ç–—ååº”ï¼Œå› æ­¤åœ¨è¯„ä¼°æ‚£è€…çš„ç–¾ç—…è¿›å±•å’Œåˆ¶å®šæ²»ç–—ç­–ç•¥æ—¶ï¼Œè¿™äº›åŸºå› å˜å¼‚çš„å­˜åœ¨å¯èƒ½æä¾›é‡è¦çš„é¢„æµ‹ä»·å€¼ã€‚